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CASE REPORT
Symmetrical Giant Facial Plaque-Type Juvenile 
Xanthogranuloma: A Case Report with a Successful 
Response to Fractional CO2 Laser Treatment
Young In Lee, Sang Ho Oh 
Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Symmetrical giant facial plaque-type juvenile xanthogranu-
loma (SGFP-JXG) is a rare variant of juvenile xanthogranulo-
ma, reported only in two cases in the literature. We report a 
case of a 3-year-old Korean boy who developed bilateral yel-
lowish indurated plaques on both cheeks since 1 year after 
birth. A skin biopsy revealed numerous foam cells and 
Touton type giant cells throughout the upper dermis, and its 
immunohistochemical studies resulted positive for CD68 
and negative for S-100. The boy was therefore diagnosed as 
a persistent SGFP-JXG. As the lesion did not show any signs 
of spontaneous regression, we performed a single session of 
fractional ablative CO2 laser, which resulted in a significant 
reduction of the lesion. This is the first case report of a persis-
tent SGFP-JXG on which a single ablative laser therapy was 
performed with a successful outcome. (Ann Dermatol 31(2) 
209∼212, 2019)
-Keywords-
Histiocytosis, Juvenile xanthogranuloma, Laser therpy, 
Xanthomatosis 
INTRODUCTION
Symmetrical giant facial plaque-type juvenile xanthogra-
nuloma (SGFP-JXG) is an uncommon type of xanthogranu-
loma, which was first described by Gunson et al.1 in 2008. 
Cutaneous manifestation of JXG typically presents as a 
solitary, well-separated yellow or red-brownish papule or 
nodule, measuring up to 1 cm in most cases2. A large or 
diffuse plaque-type lesion as shown in this case is notably 
rare. Histologically, JXG consists of a well demarcated 
mixed infiltrates of mononuclear histiocytes with vacuo-
lated cytoplasm and multinuclear giant cells, mostly Tou-
ton type giant cells, on a background of scattered lympho-
cytes, neutrophils, and mast cells3. Immunohistochemical 
staining confirms the diagnosis of JXG, with the histiocytes 
being stained in CD68. JXG is negative for protein S-100 
and CD1a, therefore differentiating it from Langerhans cell 
histiocytosis4.
Plaque types of JXG at extrafacial sites have been occa-
sionally reported in the literature2,5. SGFP-JXG, however, 
is reported only in two previous cases6. Herein, we report 
another rare case of SGFP-JXG on a 3-year-old boy, which 
persisted for 2 years without any signs of regression. This 
is the first case report of a SGFP-JXG on which a single 
fractional ablative laser therapy was performed with a 
promising outcome.
CASE REPORT 
A 3-year-old Korean boy was referred to our clinic with bi-
lateral yellowish indurated plaques on both cheeks since 
1 year after birth (Fig. 1A). Physical examinations revealed 
no ophthalmic or mucosal involvements, and palpable 
lymph nodes were not observed. Laboratory findings in-
cluding lipid profiles such as total cholesterol, triglyceride, 
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Fig. 1. We received the patient's 
consent form for publishing all 
photographic materials. (A) Initial 
photography of the bilateral sym-
metric yellowish plaques distributed 
on both cheeks. (B) Six-month 
follow-up photography after a single
session of fractional ablative CO2
laser, showing reduced sizes of the 
lesions.
high density lipoprotein–, and low density lipoprotein–
cholesterol were within normal limits. A skin biopsy was 
performed, and the histologic findings showed numerous 
foam cells with several Touton giant cells consisting of a 
lipid cytoplasm with a ring of nuclei, and occasional foreign 
body giant cells, throughout the upper dermis (Fig. 2A, B). 
The immunohistochemical staining result was positive for 
CD68 and negative for S-100 (Fig. 2C, D). Based on the 
clinicopathologic features, the patient was diagnosed as a 
SGFP-JXG. As the lesion did not show any signs of sponta-
neous regression, we performed a single session of frac-
tional ablative CO2 laser, and a significant reduction of the 
size was observed throughout the next 6 months of fol-
low-up period without signs of recurrence (Fig. 1B). 
DISCUSSION
SGFP-JXG is reported in only two case studies since 20081,6. 
In both cases, the lesions persisted for longer than 6 years, 
and had not shown a sign for spontaneous resolution. In 
one case, the 10-year-old patient simultaneously had JXG 
on the arms, and the extrafacial site disappeared sponta-
neously6. Furthermore, none of the cases observed inter-
nal organ involvements.
A confounding factor to our final diagnosis was its differ-
ential diagnosis with diffuse normolipemic plane xantho-
ma (DNPX). DNPX was first described by Altman and 
Winkelmann in 1962, and the features of this entity are: 
(a) xanthelasma palpebrarum, (b) diffuse plane xanthomas 
of the head, neck, trunk, or extremities, and (c) plasma lip-
id values that are within normal limits7,8. Its skin biopsy 
shows an accumulation of foam cells and Touton giant 
cells, along the infiltrated histiocytes that are CD68 pos-
itive, and CD1a and S-100 negative. DNPX is a rare xan-
thoma variant that has been associated with hematologic 
disorders, and only 45 cases are reported in the English lit-
erature between 1962 and 20139. Although histologically 
challenging to distinguish with JXG, DNPX typically shows 
characteristic xanthelasma appearing first in most cases, 
and tends to occur more frequently in adults8,10,11. There-
fore, the clinical presentation of our case without preced-
ing appearance of xanthelasma, the patient’s age, and its 
greater degree of similarity with the previously reported 
cases of SGFP-JXG, favors the current diagnosis. 
In conclusion, we report another rare case of SGFP-JXG 
occurred on the face of a 3-year-old boy. As shown in the 
previous reports, a subset of the lesion can persist for sev-
eral years without resolution; hence persistent lesions may 
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Fig. 2. (A, B) Haematoxylin-eosin 
staining of the yellowish plaque on 
the right cheek. Numerous foam 
cells and Touton giant cells with 
occasional foreign body giant cells 
are seen as indicated by arrows. (C) 
Immunohistochemical staining of 
the lesion showing CD68 positive 
histiocytes. (D) Immunohistoche-
mical staining of the lesion showing
a negative staining result on S-100 
(×20).
require an attempt for a treatment. A few previous DNPX 
cases, which have similar histologic features as our case, 
reported successful treatment outcomes with ablative la-
sers and dermabrasion11-13. Ablative lasers such as CO2 
and Er:YAG lasers are safe and effective devices for the re-
moval of epidermal or superficial dermal lesions. The cur-
rent report attempted a single session of fractional ablative 
CO2 laser, which resulted in a significant regression in 
size of the lesion. To our knowledge, there is only one 
other case that attempted ablative CO2 laser on xanthogra-
nulomas of the skin, and it reported some scarring left af-
ter the laser therapy14. The use of fractional laser in our 
case might have contributed to the avoidance of post-laser 
scarring, since limited ablation was induced at each mi-
crothermal zone, thus augmenting collagen remodeling 
with a decreased risk of scarring compared to fully abla-
tive technology15. A long term follow-up after the treat-
ment showed a continuous effect of the treatment. Hence, 
this is the first case report of a persistent SGFP-JXG on 
which a single fractional ablative laser therapy was per-
formed with a promising outcome. 
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